ChemoCentryx Announces Plenary Session at ACR Convergence 2020 to Highlight Findings of ADVOCATE Phase III Trial in ANCA-Associated Vasculitis
06 nov. 2020 08h30 HE
|
ChemoCentryx, Inc.
-- Study Showed Treatment with Avacopan Achieved Statistical Superiority in Sustaining Remission at 52 Weeks and Greater Improvement in Renal Function Compared to the Prednisone Group -- MOUNTAIN...
ChemoCentryx and VFMCRP announce European Medicines Agency has accepted to review the Marketing Authorization Application for avacopan
03 nov. 2020 08h30 HE
|
ChemoCentryx, Inc.
Companies have completed the EU regulatory application for marketing approval of avacopanRegulatory submission based on positive data from the pivotal Phase-III ADVOCATE trial of avacopan ST. GALLEN,...
ChemoCentryx to Hold Third Quarter 2020 Financial Results Conference Call on Monday, November 9, 2020
02 nov. 2020 08h30 HE
|
ChemoCentryx, Inc.
MOUNTAIN VIEW, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's third quarter 2020 financial results will be released after market...
ChemoCentryx Announces Positive Topline Results of Phase II AURORA Clinical Trial of Avacopan in the Treatment of Hidradenitis Suppurativa (HS)
28 oct. 2020 16h01 HE
|
ChemoCentryx, Inc.
-- Avacopan demonstrates statistically significant dose-dependent improvement in HiSCR (Hidradenitis Suppurativa Clinical Response) vs. placebo in pre-specified Hurley Stage III (severe HS) patients...
ChemoCentryx Announces FDA Acceptance of the Avacopan New Drug Application (NDA) for the Treatment of ANCA-Associated Vasculitis
17 sept. 2020 08h30 HE
|
ChemoCentryx, Inc.
-- FDA sets PDUFA goal date of July 7, 2021 -- MOUNTAIN VIEW, Calif., Sept. 17, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the U.S. Food and Drug...
ChemoCentryx to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
08 sept. 2020 08h30 HE
|
ChemoCentryx, Inc.
MOUNTAIN VIEW, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the...
ChemoCentryx Reports Second Quarter 2020 Financial Results and Recent Highlights
10 août 2020 16h05 HE
|
ChemoCentryx, Inc.
-- U.S. New Drug Application (NDA) submitted for avacopan in ANCA-associated vasculitis -- -- Balance sheet bolstered with $325.7 million in net proceeds from June follow-on offering; total cash,...
ChemoCentryx to Present at Two Upcoming Investor Conferences
04 août 2020 08h30 HE
|
ChemoCentryx, Inc.
MOUNTAIN VIEW, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at two...
ChemoCentryx to Hold Second Quarter 2020 Financial Results Conference Call on Monday, August 10, 2020
03 août 2020 08h30 HE
|
ChemoCentryx, Inc.
MOUNTAIN VIEW, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's second quarter 2020 financial results will be released after market...
ChemoCentryx Submits New Drug Application to the U.S. FDA for Avacopan in ANCA-Associated Vasculitis
09 juil. 2020 08h30 HE
|
ChemoCentryx, Inc.
MOUNTAIN VIEW, Calif., July 09, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ: CCXI) today confirmed that the Company has submitted a New Drug Application (NDA) to the U.S. Food and Drug...